<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="758">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00164086</nctid>
  <trial_identification>
    <studytitle>Atorvastatin in Myeloma</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>7/04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Myeloma</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - atorvastatin

Treatment: drugs: atorvastatin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>-  Myeloma in remission</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Adverse events (AEs) to statin, already on a statin, or contraindication to statin</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <postcode>3181 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Bayside Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to study the effects of a medication already widely used to
      treat cardiovascular disease and diabetes, in reducing the progression of myeloma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00164086</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Spencer, MBChB, FRACP, PhD</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jennifer Martin, MBChB, FRACP</name>
      <address />
      <phone>0405 341 676</phone>
      <fax />
      <email>jennifer.martin@med.monash.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>